Original Article
28 June 2017 / 17 April 2024 by almaware
Read more »
Letter to the Editor
Case Report
27 June 2017 / 17 April 2024 by almaware
Review
27 June 2017 / 23 May 2024 by almaware
Monoclonal anti-IgE antibodies (omalizumab) are able to induce clinically significant benefits in patients with severe chronic spontaneous urticaria (CS). Those results led clinicians and investigators to reconsider a possible pathogenic role not previously supported for IgE and its receptors in this disease, and to investigate additional approaches for understanding its pathogenesis. IgE antibodies to unknown […]
5 May 2017 / 17 April 2024 by almaware
The first case of disappearance of apple-induced oral allergy syndrome in a birch pollen-allergic patient following omalizumab treatment is reported. This observation in a case of type 2 food allergy suggests that omalizumab is potentially an effective preventive treatment for patients with severe, type 1 food allergies.
Rhinitis and sinusitis usually coexist and are concurrent in most individuals; thus, the correct terminology is now “rhinosinusitis”. On the basis of numerous causative factors, often co-existing in the same patient, the diagnosis of rhinosinusitis is also made by a wide variety of practitioners (allergologists, otolaryngologists, pulmonologists, primary care physicians, paediatricians, and many others). Approximately […]